XML 71 R60.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value - Additional Information (Details)
3 Months Ended 6 Months Ended
Feb. 12, 2026
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Fair Value            
Transfers between Level 1 to Level 2       $ 0    
Transfers between Level 2 to Level 1       0    
Fair value of contingent consideration   $ 136,304,000   136,304,000   $ 0
Fair value of the contingent consideration increased   26,800,000   26,800,000    
Change in contingent consideration   $ 26,414,000 $ 0 26,414,000 $ 0  
Recognized share-based compensation expense $ 18,400,000     $ 400,000    
Avadel Pharmaceuticals Plc            
Fair Value            
Recognized share-based compensation expense $ 1,800,000          
Avadel Pharmaceuticals Plc | Minimum            
Fair Value            
Percentage of success of achieving the CVR Milestone       75.00%    
Avadel Pharmaceuticals Plc | Maximum            
Fair Value            
Percentage of success of achieving the CVR Milestone       90.00%    
Avadel Pharmaceuticals Plc | Discount Rate            
Fair Value            
Discount rate   0.0618   0.0618    
Fair Value Level 2            
Fair Value            
Unrelaised amount       $ 1,532,400,000